Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
The European Journal of Neuroscience
|
August 8, 2001
Roles of the glutamate receptor epsilon2 and delta2 subunits in the potentiation and prepulse inhibition of the acoustic startle reflex
T Takeuchi, Y Kiyama, K Nakamura, et al.
Neuroscience Letters
|
November 8, 2001
Brainstem auditory regions in mice: expression of nociceptin/orphanin FQ precursor mRNA in select neurons
S Kakimoto, T Houtani, K Sato, et al.
Neuroscience Letters
|
August 27, 1998
Auditory pathway and auditory brainstem response in mice lacking NMDA receptor epsilon 1 and epsilon 4 subunits
Y Munemoto, H Kuriyama, T Doi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2016
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)
E Oki, A Murata, K Yoshida, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2016
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial)
M Kanai, T Kawaguchi, M Kotaka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 25, 2015
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study
S Iwamoto, T Takahashi, H Tamagawa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2020
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
K Yamazaki, T Yamanaka, M Shiozawa, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 25, 2019
SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer
Y Munemoto, M Nakamura, M Takahashi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2021
Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy
M Kanai, T Kawaguchi, M Kotaka, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
The European Journal of Neuroscience
|
August 8, 2001
Roles of the glutamate receptor epsilon2 and delta2 subunits in the potentiation and prepulse inhibition of the acoustic startle reflex
T Takeuchi, Y Kiyama, K Nakamura, et al.
Neuroscience Letters
|
November 8, 2001
Brainstem auditory regions in mice: expression of nociceptin/orphanin FQ precursor mRNA in select neurons
S Kakimoto, T Houtani, K Sato, et al.
Neuroscience Letters
|
August 27, 1998
Auditory pathway and auditory brainstem response in mice lacking NMDA receptor epsilon 1 and epsilon 4 subunits
Y Munemoto, H Kuriyama, T Doi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2016
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)
E Oki, A Murata, K Yoshida, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2016
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial)
M Kanai, T Kawaguchi, M Kotaka, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 25, 2015
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study
S Iwamoto, T Takahashi, H Tamagawa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 30, 2020
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
K Yamazaki, T Yamanaka, M Shiozawa, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 25, 2019
SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer
Y Munemoto, M Nakamura, M Takahashi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2021
Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy
M Kanai, T Kawaguchi, M Kotaka, et al.
Page
of 2